BusinessMersana Announces Third Quarter 2017 Financial Results and Provides Business UpdatesBy Nasdaq OMXNov 9, 2017, 9:01 PM UTC
BusinessMersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2bBy Nasdaq OMXOct 30, 2017, 11:30 AM UTC
BusinessMersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International ConferenceBy Nasdaq OMXOct 30, 2017, 11:00 AM UTC
BusinessMersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBy Nasdaq OMXOct 23, 2017, 8:01 PM UTC
